12:00 AM
Sep 16, 2016
 |  BC Extra  |  Clinical News

Biogen ties anti-LINGO miss to non-linear dose response

Biogen Inc. (NASDAQ:BIIB) suggested a non-linear dose response to opicinumab ( BIIB033) could have led to the compound's failure to meet the primary endpoint in the Phase II SYNERGY study to treat relapsing forms of multiple sclerosis (MS). Biogen hopes the mAb against leucine-rich repeat neuronal protein 1 ( LINGO-1) can reverse the course of MS by allowing remyelination.

In June, opicinumab missed SYNERGY's composite...

Read the full 328 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >